Andrew A. Lane, MD, PhD

Andrew A. Lane, MD, PhD

Medical Oncology

Contact Information

Office Phone Number







Andrew A. Lane, MD, PhD

Dr. Lane received his MD and PhD degrees from Washington University. He completed his residency in internal medicine at Brigham and Women's Hospital, and his fellowships in hematology and medical oncology at DFCI. His research focuses on developing new treatments for leukemia by studying the genetic changes that occur in cancer and how they alter the normal development of blood cells.



Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Center
Associate Professor of Medicine, Harvard Medical School


Adult Leukemia Program
Stem Cell Transplantation

Clinical Interests

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Leukemias, Stem cell transplantation

Diseases Treated

Board Certification

  • Hematology, 2012
  • Internal Medicine, 2009
  • Medical Oncology, 2012


  • Dana-Farber/Partners CancerCare, Hematology/Oncology


  • Brigham and Women's Hospital, Internal Medicine

Medical School

  • Washington University

Recent Awards

  • Seldin-Smith Award for Pioneering Research, American Society for Clinical Investigation (ASCI), 2020


    Developing new treatments for leukemia

    The Lane lab strives to expose and target the abnormal biology that drives blood cancers, particularly those with poor prognoses or without specific treatments.  We focus predominantly on acute leukemia and the disruption of normal stem cell development in hematologic malignancies.

    Our goal is to understand the genetic and epigenetic changes that alter gene regulation in malignant hematopoietic cells, develop innovative model systems to study those abnormalities, and ultimately discover novel therapeutic strategies.  We hope that our research leads to better tolerated therapies and more cures for patients with leukemia and other blood disorders.

    We are also committed to training the next generation of physicians and scientists who will be future leaders in cancer research and clinical-translational innovation.


      • Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival. Blood Adv. 2024 Apr 11. View in: Pubmed

      • Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399. View in: Pubmed

      • Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma. 2024 Feb 23; 1-12. View in: Pubmed

      • Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602. View in: Pubmed

      • Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2024 Jan 01; 109(1):44-52. View in: Pubmed

      • AMPK activation induces immunogenic cell death in AML. Blood Adv. 2023 12 26; 7(24):7585-7596. View in: Pubmed

      • Targetable leukemia dependency on noncanonical PI3K? signaling. bioRxiv. 2023 Dec 15. View in: Pubmed

      • Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow. Mod Pathol. 2024 Jan; 37(1):100352. View in: Pubmed

      • DDX41: here, there…and everywhere. Blood. 2023 10 05; 142(14):1177-1178. View in: Pubmed

      • Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581. View in: Pubmed

      • Enhancing dendritic cells by inhibiting BCL2. Trends Cancer. 2023 12; 9(12):987-988. View in: Pubmed

      • Leukemia circulation kinetics revealed through blood exchange method. bioRxiv. 2023 Sep 05. View in: Pubmed

      • Loss of chromosome Y in primary tumors. Cell. 2023 Jun 22. View in: Pubmed

      • Genomics of PDGFR-rearranged hypereosinophilic syndrome. Blood Adv. 2023 06 13; 7(11):2558-2563. View in: Pubmed

      • Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023 Jun; 618(7966):834-841. View in: Pubmed

      • False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay. Acta Haematol. 2023; 146(4):316-321. View in: Pubmed

      • Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. Am J Clin Pathol. 2023 05 02; 159(5):455-463. View in: Pubmed

      • North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. View in: Pubmed

      • Novel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease. JAAD Case Rep. 2023 Mar; 33:67-69. View in: Pubmed

      • Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036. View in: Pubmed

      • Peripheral blood CD3+ T-cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. Br J Haematol. 2022 10; 199(1):100-105. View in: Pubmed

      • Assessing the Antimicrobial Properties of Copper-Iodide Doped Adhesives in an In vitro Caries Model: A Pilot Study. Contemp Clin Dent. 2022 Apr-Jun; 13(2):118-124. View in: Pubmed

      • Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma. 2022 11; 63(11):2757-2759. View in: Pubmed

      • Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11). View in: Pubmed

      • Shared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient. Am J Dermatopathol. 2022 12 01; 44(12):929-932. View in: Pubmed

      • CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2022 May 03; 14(9). View in: Pubmed

      • Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228. View in: Pubmed

      • Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 08; 63(8):1934-1941. View in: Pubmed

      • Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm. Front Immunol. 2022; 13:809414. View in: Pubmed

      • Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations. Nat Biotechnol. 2022 07; 40(7):1030-1034. View in: Pubmed

      • AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Rep. 2022 01 04; 38(1):110197. View in: Pubmed

      • Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discov. 2022 02; 12(2):522-541. View in: Pubmed

      • Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480. View in: Pubmed

      • Targeting CD123 in AML. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S67-S68. View in: Pubmed

      • Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. Leuk Lymphoma. 2020 09; 61(9):2258-2261. View in: Pubmed

      • Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 03 24; 4(6):1006-1011. View in: Pubmed

      • Blastic Plasmacytoid Dendritic Cell Neoplasm in 2020 and Beyond. Hematol Oncol Clin North Am. 2020 06; 34(3):xiii-xiv. View in: Pubmed

      • Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 06; 34(3):589-600. View in: Pubmed

      • Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020 03 16; 11(1):1406. View in: Pubmed

      • DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 11 01; 129(11):5005-5019. View in: Pubmed

      • Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):941-946. View in: Pubmed

      • Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687. View in: Pubmed

      • Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):545-554. View in: Pubmed

      • Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. J Glob Oncol. 2019 06; 5:1-6. View in: Pubmed

      • Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508. View in: Pubmed

      • Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637. View in: Pubmed

      • Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459. View in: Pubmed

      • Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019 03 07; 176(6):1265-1281.e24. View in: Pubmed

      • More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med. 2019 02 14; 380(7):695-6. View in: Pubmed

      • Improving Aseptic Technique During the Treatment of Pediatric Septic Shock: A Comparison of 2 Rapid Fluid Delivery Methods. J Infus Nurs. 2019 Jan/Feb; 42(1):23-28. View in: Pubmed

      • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Curr Hematol Malig Rep. 2018 12; 13(6):581-587. View in: Pubmed

      • Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Rep. 2018 11 13; 25(7):1898-1911.e5. View in: Pubmed

      • Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. 2017 12; 12(6):592-597. View in: Pubmed

      • Monogenic Hashimoto thyroiditis associated with a variant in the thyroglobulin (TG) gene. J Autoimmun. 2018 01; 86:116-119. View in: Pubmed

      • Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv. 2017 Aug 22; 1(19):1491-1494. View in: Pubmed

      • Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017 04 21; 356(6335). View in: Pubmed

      • Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164. View in: Pubmed

      • Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep. 2016 12; 11(6):462-467. View in: Pubmed

      • Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

      • Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. View in: Pubmed

      • Outcome of Isolated Premature Menarche: A Retrospective and Follow-Up Study. Horm Res Paediatr. 2015; 84(4):217-22. View in: Pubmed

      • Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1046-1053. View in: Pubmed

      • Mutations in G protein ß subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan; 21(1):71-5. View in: Pubmed

      • Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014 Nov 11; 3(5):832-40. View in: Pubmed

      • Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8. View in: Pubmed

      • Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23. View in: Pubmed

      • A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6. View in: Pubmed

      • Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117. View in: Pubmed

      • Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71. View in: Pubmed

      • Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One. 2012; 7(11):e49201. View in: Pubmed

      • Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73. View in: Pubmed

      • Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6. View in: Pubmed

      • Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55. View in: Pubmed

      • High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1363-6. View in: Pubmed

      • Stem cells and DNA damage: persist or perish? Cell. 2010 Aug 06; 142(3):360-2. View in: Pubmed

      • A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood. 2010 Nov 04; 116(18):3604-10. View in: Pubmed

      • von Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy. Am J Hematol. 2010 Feb; 85(2):134-5. View in: Pubmed

      • Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10; 27(32):5459-68. View in: Pubmed

      • Acute myeloid leukemia in first complete remission: How do we select patients for allogeneic stem cell transplantation?. American Journal of Hematology/Oncology. 2009; 8(10):508-511. View in: Pubmed

      • Pathogenesis of acute promyelocytic leukemia [dissertation]. 2006. View in: Pubmed

      • Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005 Aug; 90(8):1042-9. View in: Pubmed

      • Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol. 2005 Jan; 25(1):23-33. View in: Pubmed

      • Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol. 2004 Dec; 24(24):10882-93. View in: Pubmed

      • Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell. 2003 Oct 31; 115(3):305-18. View in: Pubmed

      • High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003 Sep 01; 102(5):1857-65. View in: Pubmed

      • Mouse models of acute promyelocytic leukemia. Curr Opin Hematol. 2001 Jul; 8(4):206-11. View in: Pubmed

      • Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J. 1999 Apr 15; 18(8):2165-73. View in: Pubmed

      • Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998 Mar 01; 12(5):667-78. View in: Pubmed

      • Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem. 1998 Jan 16; 273(3):1303-8. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 413 Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Mayer 413 Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Andrew A. Lane, MD, PhD

      About Our Ratings

      Physician Star Rating Comment Block